Cytoreductive surgery and perioperative intraperitoneal chemotherapy in recurrent ovarian cancer

Tumori

Volumn 96, Issue 3, 2010, Pages 411-416

  Tentes, Antonios Apostolos K ^a   Korakianitis, Odysseas S ^a   Kakolyris, Stylianos ^b   Kyziridis, Dimitrios ^a   Veliovits, Dousan ^a   Karagiozoglou, Chrysa ^a   Sgouridou, Evanthia ^a   Moustakas, Konstantinos ^a  

^a Didimotichon General Hospital   (Greece)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Cytoreductive surgery; Intraperitoneal chemotherapy; Morbidity mortality; Recurrent ovarian cancer; Survival

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; TAXANE DERIVATIVE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; CYTOREDUCTIVE SURGERY; DEVICE; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HUMAN; HYPERTHERMIC THERAPY; MORBIDITY; MORTALITY; NEUTROPENIA; OVARY CANCER; OVERALL SURVIVAL; PERIOPERATIVE PERIOD; PERITONEUM CANCER; POSTOPERATIVE CARE; RECURRENT CANCER; RESPIRATORY FAILURE; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME; WOUND INFECTION;

EID: 77954970893     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089161009600306     Document Type: Article

References (32)

1. Chen LM, Karlan BY: Recurrent ovarian carcinoma: Is there a place for surgery? Semin Surg Oncol, 19: 62-68, 2000.
2. Rose PG: Surgery for recurrent ovarian cancer. Semin Oncol, 27: 17-23, 2000.
3. Eisenkop SM, Friedman RL, Spirtos NM: The role of secondary surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer, 88: 144-153, 2000.
4. Scarabelli C, Gallo A, Carbone A: Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol, 83: 504-512, 2001.
5. Pfisterer J, Harker P, Canzler M, Richter B, Jackisch C, Hahmann M, Hasenburg A, Burges A, Loibl S, Gropp M, Hueber J, Fink D, Bois A, AGO Ovarian Committee, AGO Ovarian Study Group (AGO-OVAR): The role of surgery in recurrent ovarian cancer. Int J Gynecol Cancer, suppl 3: 195-198, 2005.
6. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ: Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinumera: a meta-analysis. J Clin Oncol, 20: 1248-1259, 2002.
7. Tentes AA, Mirelis CG, Markakidis CK, Bekiaridou KA, Bougioukas IG, Xanthoulis AI, Tsalkidou EG, Zafiropoulos GH, Nikas IH: Long-term survival in advanced ovarian carcinoma following cytoreductive surgery with standard peritonectomy procedures. Int J Gynecol Cancer, 16: 490-495, 2006.
8. Tay EH, Grabt PT, Gebeki V, Hacker NF: Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Obstet Gynecol, 99: 1008-1013, 2002.
9. Deraco M, Rossi CR, Penacchioli E, Guadagni S, Somers DC, Santoro N, Raspagliesi F, Kusamura S, Vaglini M: Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion in the treatment of recurrent epithelial ovarian cancer: a phase II clinical study. Tumori, 87: 120-126, 2001.
10. Look M, Chang D, Sugarbaker PH: Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum. Int J Gynecol Cancer, 13: 764-770, 2003.
11. Piso P, Dahlke MH, Loss M, Schlitt HJ: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer. World J Surg Oncol, 2: 21, 2004.
12. Zang RY, Zang ZY, Li LT, Chen J, TangMG, Liu Q, Cai SM: Effect of cytoreductive surgery on survival of patients with recurrent epithelial ovarian cancer. EJSO, 26: 798-804, 2000.
13. Eisenkop SM, Friedman RL, Wang HJ: Secondary cytoreductive surgery for recurrent ovarian cancer. A prospective study. Cancer, 76: 1606-1614, 1995.
14. Sugarbaker PH: Management of peritoneal surface malignancy: the surgeon's role. Langenbeck's Arch Surg, 384: 576-587, 1999.
15. Sugarbaker PH: Management of peritoneal surface malignancy using intraperitoneal chemotherapy and cytoreductive surgery. A manual for physicians and nurses. 3d ed, Grand Rapids, Michigan: Ludann Co, 1998.
16. Randall T, and Rubin S: Cytoreductive surgery for ovarian cancer. Surg Clin N Am, 81: 871-873, 2001.
17. Michel G, Zarca D, Castaigne D, Prade M: Secondary cytoreductive surgery in ovarian cancer. EJSO, 15: 201-204, 1989.
18. Neijt J: Ovarian cancer: Rethinking Prognostic Factors and Chemotherapy, ASCO Educational Book, 214-220, 1994.
19. Memarzadeh S, and Berek J: Advances in the management of epithelial ovarian cancer. J Reprod Med, 46: 621-629, 2001.
20. Meier W, du Bois A, Kuhn W, Olbricht S, Gropp M, Richter B, Luck HJ, Kimmig R, Pfisterer J: Topotecan versus treosulfan, an alkylating agent in patients with epithelial ovarin cancer and relapse within 12 months following 1stline platinum/paclitaxel chemotherapy: A prospective randomized phase III trial by the Arbeitsgemeinschaft Gynaecologische Onkologie Ovarian Cancer Group (AGO-OVAR). Gynecol Oncol, 114: 199-205, 2009.
21. Tanguay JS, Ansari J, Buckley L, Fernando I: Epithelial ovarian cancer: role of pegylated liposomal Doxorubicin in prolonging the platinum-free interval and cancer antigen 125 trends during treatment. Int J Gynecol Cancer, 19: 361-366, 2009.
22. Sugarbaker P: Peritonectomy procedures. Ann Surg, 221: 29-42, 1995.
23. Sugarbaker TA, Sugarbaker PH: Pathophysiology of peritoneal carcinomatosis from ovarian malignancy. In: Sugarbaker PH (ed) Peritoneal Carcinomatosis: Drugs and Diseases, Norwell, MA: Kluwer Academic Publishers, pp 247-261, 1996.
24. Sugarbaker P, and Chang D: Results of treatment of 358 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol, 6: 727-731, 1999.
25. van Ruth S, Ackerman Y, van de Vijver M, Hart A, Verwaal V, Zoetmulder F: Pseudomyxoma peritonei: a review of 62 cases. EJSO, 29: 682-688, 2003.
26. Verwaal V, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, Zoetmulder FA: Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol, 21: 3737-3739, 2003.
27. Yu W, Whang I, Suh I, Averbach A, Chang D, Sugarbaker P: Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer. Ann Surg, 228: 347-354, 1998. (Pubitemid 30191697)
28. Begossi G, Gonzalez-Moreno S, Ortega-Perez G, Fon L, Sugarbaker P: Cytoreduction and intraperitoneal chemotherapy for the management of peritoneal carcinomatosis, sarcomatosis and mesothelioma. EJSO, 28: 80-87, 2002.
29. Di Giorgio A, Naticchioni E, Biacchi D, Sibio S, Accarpio F, Rocco M, Tarquini S, Di Seri M, Ciardi A, Montruccoli D, Sammartino R: Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer. Cancer, 15: 315-325, 2008.
30. Tentes AAK, Tripsiannis G, Markakidis SK, Karanikiotis CN, Tzegas G, Georgiadis G, Avgidou K: Peritoneal cancer index: a prognostic indicator of survival in advanced ovarian cancer. EJSO, 29: 69-73, 2003.
31. Ferguson MK: The effect of antineoplastic agents on wound healing. Surg Gynecol Obstet, 154: 421-428, 1982.
32. Fernandez-Trigo F, Stuart OA, Stephens A, Hoover L, Sugarbaker PH: Surgically directed chemotherapy: heated intraperitoneal lavage with mitomycin C. In: Peritoneal Carcinomatosis: Drugs and Diseases, Sugarbaker PH (Ed), pp 51-61, Kluwer Academic, Norwell (MA), 1996.